Acasti Pharma, Inc. (ACST)

Acasti Pharma (ACST) Stock Price & Analysis


ACST Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.72 - $5.05
Previous Close$2.78
Average Volume (3M)62.86K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$21.65M
Total Debt (Recent Filing)$80.00K
Price to Earnings (P/E)-0.5
Nov 15, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.64
Shares Outstanding7,448,033
10 Day Avg. Volume241,615
30 Day Avg. Volume62,860
Standard Deviation0.36
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Price Target Upside331.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Acasti Pharma, Inc.’s price range in the past 12 months?
Acasti Pharma, Inc. lowest stock price was $1.72 and its highest was $5.05 in the past 12 months.
    What is Acasti Pharma, Inc.’s market cap?
    Currently, no data Available
    When is Acasti Pharma, Inc.’s upcoming earnings report date?
    Acasti Pharma, Inc.’s upcoming earnings report date is Nov 15, 2023 which is in 46 days.
      How were Acasti Pharma, Inc.’s earnings last quarter?
      Acasti Pharma, Inc. released its earnings results on Aug 11, 2023. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.26.
        Is Acasti Pharma, Inc. overvalued?
        According to Wall Street analysts Acasti Pharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Acasti Pharma, Inc. pay dividends?
          Acasti Pharma, Inc. does not currently pay dividends.
          What is Acasti Pharma, Inc.’s EPS estimate?
          Acasti Pharma, Inc.’s EPS estimate is -$0.32.
            How many shares outstanding does Acasti Pharma, Inc. have?
            Acasti Pharma, Inc. has 7,448,033 shares outstanding.
              What happened to Acasti Pharma, Inc.’s price movement after its last earnings report?
              Acasti Pharma, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Acasti Pharma, Inc.?
                Currently, no hedge funds are holding shares in ACST


                Acasti Pharma Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Acasti Pharma, Inc.

                Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.


                Top 5 ETFs holding ACST

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold ACST. The ETFs are listed according to market value of ACST within the ETF

                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Acer Therapeutics
                ADMA Biologics
                DMK Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis